These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 7608313)

  • 1. Novel galactose single point method as a measure of residual liver function: example of cefoperazone kinetics in patients with liver cirrhosis.
    Hu OY; Tang HS; Chang CL
    J Clin Pharmacol; 1995 Mar; 35(3):250-8. PubMed ID: 7608313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of chronic lobular hepatitis on pharmacokinetics of cefoperazone--a novel galactose single-point method as a measure of residual liver function.
    Hu OY; Tang HS; Chang CL
    Biopharm Drug Dispos; 1994 Oct; 15(7):563-76. PubMed ID: 7849232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of liver function using a novel galactose single point method.
    Tang HS; Hu OY
    Digestion; 1992; 52(3-4):222-31. PubMed ID: 1334011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of promazine in patients with hepatic cirrhosis--correlation with a novel galactose single point method.
    Hu OY; Tang HS; Sheeng TY; Chen TC; Curry SH
    J Pharm Sci; 1995 Jan; 84(1):111-4. PubMed ID: 7714731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cefoperazone pharmacokinetics in patients with liver cirrhosis: a predictive value of the ujoviridin test.
    Saudek F; Morávek J; Modr Z
    Int J Clin Pharmacol Ther Toxicol; 1989 Feb; 27(2):82-7. PubMed ID: 2921099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of cefoperazone and sulbactam in liver transplant patients.
    Muder RR; Agarwala S; Mirani A; Gayowski T; Venkataramanan R
    J Clin Pharmacol; 2002 Jun; 42(6):644-50. PubMed ID: 12043952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of cefoperazone (2.0 g) and sulbactam (1.0 g) coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis.
    Reitberg DP; Marble DA; Schultz RW; Whall TJ; Schentag JJ
    Antimicrob Agents Chemother; 1988 Apr; 32(4):503-9. PubMed ID: 3377461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of hyperglycemia on quantitative liver functions by the galactose load test in diabetic rats.
    Young TH; Tang HS; Lee HS; Hsiong CH; Hu OY
    Metabolism; 2007 Sep; 56(9):1265-9. PubMed ID: 17697871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Splanchnic galactose uptake in patients with cirrhosis during continuous infusion.
    Lindskov J; Ranek L; Tygstrup N; Winkler K
    Clin Physiol; 1983 Apr; 3(2):179-85. PubMed ID: 6682739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimation of the hepatic blood "flow" by galactose plasma clearance in patients with liver disease.
    Zaramella MG; Vallini R; Tiribelli C
    Liver; 1985 Jun; 5(3):129-33. PubMed ID: 4046751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacokinetic study of a cephalosporin, cefoperazone, in liver failure].
    Belaieff J; Cochet B; Allaz AF; Rudhardt M; Balant L; Fabre J
    Schweiz Med Wochenschr; 1981 Apr; 111(14):502-8. PubMed ID: 6453423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary sodium balance in patients with cirrhosis: relationship to quantitative parameters of liver function.
    Wensing G; Lotterer E; Link I; Hahn EG; Fleig WE
    Hepatology; 1997 Nov; 26(5):1149-55. PubMed ID: 9362355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple-dose pharmacokinetics of rufloxacin in patients with cirrhosis.
    Triger DR; Granai F; Woodcock J; Wise R; Imbimbo BP
    Hepatology; 1993 Oct; 18(4):847-52. PubMed ID: 8406358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-order clearance of plasma galactose: the effect of liver disease.
    Henderson JM; Kutner MH; Bain RP
    Gastroenterology; 1982 Nov; 83(5):1090-6. PubMed ID: 7117792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uncertainty in liver function assessment on the basis of single-point galactose concentration.
    Fabbri A; Bianchi G; Brizi M; Zoli M; Marchesini G
    Digestion; 1997; 58(4):379-83. PubMed ID: 9324166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Steady-state pharmacokinetics of cefoperazone and sulbactam in patients with acute appendicitis.
    Danziger LH; Piscitelli SC; Occhipinti DJ; Resnick DJ; Rodvold KA
    Ann Pharmacother; 1994 Jun; 28(6):703-7. PubMed ID: 7919553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefoperazone pharmacokinetics in normal subjects and patients with cirrhosis.
    Boscia JA; Korzeniowski OM; Snepar R; Kobasa WD; Levison ME; Kaye D
    Antimicrob Agents Chemother; 1983 Mar; 23(3):385-9. PubMed ID: 6221691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic amino-nitrogen clearance to urea-nitrogen in control subjects and in patients with cirrhosis: a simplified method.
    Bianchi G; Marchesini G; Vilstrup H; Fabbri A; De Mitri MS; Zoli M; Pisi E
    Hepatology; 1991 Mar; 13(3):460-6. PubMed ID: 1999317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of metoprolol in patients with hepatic cirrhosis.
    Regårdh CG; Jordö L; Ervik M; Lundborg P; Olsson R; Rönn O
    Clin Pharmacokinet; 1981; 6(5):375-88. PubMed ID: 7333059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Caffeine clearance test: a quantitative liver function assessment in patients with liver cirrhosis.
    Shyu JK; Wang YJ; Lee SD; Lu RH; Lo KJ
    Zhonghua Yi Xue Za Zhi (Taipei); 1996 May; 57(5):329-34. PubMed ID: 8768380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.